Increase federal funding for pediatric cancer research.

Rather than ending federal investments into essential studies and clinical trials that could provide the pathway to better treatments and an eventual cure, we should be increasing funding for pediatric cancer research.

Cleaver said federal investments in pediatric cancer studies and clinical trials should be increased rather than ended.

Cleaver, Davids Demand Answers on Halted Pediatric Brain Cancer Research | Congressman Emanuel Cleaver
primary · press_release · model gpt-5.5

NIH says the RCDC table was published June 23, 2026, shows historical FY2008-FY2025 category data, and does not provide FY2026/FY2027 category estimates at this time.

Latest lookback-window official update did not show a new FY2026 pediatric-cancer funding increase; it leaves current-year category funding unresolved while preserving historical funding data.

unresolved later_term

NIH RePORT: Funding for Various Research, Condition, and Disease Categories (RCDC)
secondary · model gpt-5.5 · confidence 78%

NCI states CCDI is a $50 million federal investment made in each fiscal year since 2020, with another $50 million proposed each fiscal year for 10 years.

Official NCI evidence that federal pediatric cancer research/data funding increased through a recurring $50 million annual investment beginning in FY2020.

delivered later_term

National Cancer Institute: About the Childhood Cancer Data Initiative (CCDI)
secondary · model gpt-5.5 · confidence 90%

On December 17, 2019, H.R. 1865 passed the House 297-120; the Clerk records Rep. Cleaver as voting Yea.

Cleaver voted for the FY2020 consolidated appropriations vehicle associated with the launch year of NCI's $50 million annual Childhood Cancer Data Initiative investment.

delivered later_term A for effort

Office of the Clerk, U.S. House: Roll Call 689, H.R. 1865
secondary · model gpt-5.5 · confidence 82%

Congress.gov records H.R.3391 became Public Law 118-228 on January 4, 2025; CRS summary says it reauthorizes NIH's pediatric disease research initiative through FY2028.

A pediatric research funding initiative was extended into future fiscal years, supporting continued federal pediatric research funding during Cleaver's later House service.

partial later_term

Congress.gov: H.R.3391 - Gabriella Miller Kids First Research Act 2.0
secondary · model gpt-5.5 · confidence 86%

The Clerk records H.R.3391, Gabriella Miller Kids First Research Act 2.0, passed 384-4 on March 5, 2024; Cleaver voted Yea.

Cleaver took a concrete recorded vote for the bill later enacted to extend the NIH pediatric research initiative through FY2028.

partial later_term A for effort

Office of the Clerk, U.S. House: Roll Call 60, H.R. 3391
secondary · model gpt-5.5 · confidence 90%

Congress.gov records the Childhood Cancer STAR Act became Public Law 115-180; its summary says NIH may support specimen and information collection for children, adolescents, and young adults with selected cancers.

The federal government enacted a pediatric cancer research law during Cleaver's House tenure; the House passed it by voice vote, so no individual Cleaver roll-call position is available from this source.

partial later_term

Congress.gov: S.292 - Childhood Cancer STAR Act
secondary · model gpt-5.5 · confidence 80%